Olaparib Tablets Maintenance Monotherapy Ovarian Cancer patients after Complete or Partial Response to Platinum Chemotherapy

Trial Identifier: D0816C00016
Sponsor: AstraZeneca
NCTID:: NCT03534453
Start Date: May 2018
Primary Completion Date: December 2024
Study Completion Date: December 2024
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100142
CN Changsha, CN, 410013
CN Chengdu, CN, 610041
CN Chongqing, CN, 400030
CN Chongqing, CN, 400038
CN Hangzhou, CN, 310022
CN Hangzhou, CN, 310006
CN Harbin, CN, 150081
CN Hefei, CN, 230031
CN Jinan, CN, 250012
CN shanghai, CN, 200011
CN Shanghai, CN, 200080
CN Shanghai, CN, 200032
CN Shenyang, CN, 110016
CN Tianjin, CN, 300060
CN Tianjin, CN
CN Wuhan, CN, 430030
CN Wuhan, CN, 430079
CN Xian, CN, 710061
CN Zhengzhou, CN, 450008
MY Ampang, MY, 68000
MY Johor Bahru, MY, 81100
MY Kuala Lumpur, MY, 59100
MY Kuching, MY, 93586
MY Putrajaya, MY, 62250